Chemical Namebremelanotide
Dosage FormInjectable (subcutaneous; 1.75 mg/0.3 mL)
Drug ClassReceptor agonists
SystemFemale reproductive
CompanyAMAG Pharmaceuticals
Approval Year2019


  • Vyleesi is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: a co-existing medical or psychiatric condition, problems with the relationship, or the effects of a medication or drug substance.
Last updated on 10/29/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Vyleesi (bremelanotide) Prescribing Information 2019Daily Med
Document TitleYearSource
Multi-discipline review. 2019FDA: Center for Drug Evaluation and Research